Affymetrix, Inc.

DNA analysis systems maker expects fourth quarter revenue to be below previous guidance

Published in Lab Business Week, February 5th, 2006

Affymetrix, Inc., (AFFX) announced that due to low fourth quarter instrument sales and delays in completing genotyping processing under a services contract, the company now expects, based on preliminary financial data, that product and product related revenue for the fourth quarter ending December 31, 2005, will be roughly $15 million below previous guidance.

"Affymetrix is experiencing growing pains as it both innovates and commercializes new products in high potential markets. Introduced about 2 years ago, our DNA analysis business has grown to around $90 million in fiscal 2005," stated Stephen P.A. Fodor, PhD, founder, chairman and CEO of Affymetrix.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-02-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry